Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 09 | 2026Madrigal Licenses MASH Assets from Pfizer; Wegovy Pill Available on Amazon; New BI MASH Asset; Alveus Launches as Clinical-Stage Biotech; Zealand Partners for AI Drug Discovery; Lilly Expands TuneLabPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jan 08 | 2026Antag Ph1 Obesity Data; Lilly Zepbound+Taltz PsA Combination Data; Rani Initiates Ph1 Dual Agonist Study; Viking Completes Ph1 VK2735 Maintenance Study Enrollment; Gordian and Pfizer Partner for Obesity Drug Discovery; MannKind Provides 2026 Business UpdatesPurchase Blast
$599
Posted in: Other, Topics Jan 07 | 2026Lilly Initiates Second Ph3 Eloralintide Trial; Lilly Acquires Ventyx; Monte Rosa Interim Ph1 Data; Corsera Series A FundingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 07 | 2026Arrowhead Ph1/2 RNAi-Based Obesity Results; MindRank Ph3 Oral GLP-1RA Program; Altimmune Receives Breakthrough Therapy Designation; Nimbus and Lilly Partner for Obesity; Roche and Structure Patent Agreement; Novo Debuts Report on America’s Obesity EpidemicPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 06 | 2026Holiday Hangover: Novo Launches Wegovy Pill; Additional Companies Engage in MFN Deals; Pfizer Initiates Ph3 Obesity Program of MET097i; and MorePurchase Blast
$599
Posted in: Dual/triple agonist, Topics Dec 19 | 2025Altimmune Topline Ph2 Pemvidutide MASH DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 18 | 2025Lilly’s Ph3 ATTAIN-MAINTAIN Results; Orforglipron Filed; Novo Files Cagrisema and Receives FDA Warning Letter; Merck to Receive CNPV; SAB BIO Pivotal Ph2b T1DM Trial; Sagimet Enters Agreement for ResmetiromPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 17 | 2025Kailera Initiates H2H Study Vs. Semaglutide; Structure Initiates Ph1 Amylin Study; Rona Unveils Bivalent siRNA; Lilly Partners for Obesity Drug Discovery and Initiates Brenipatide Ph2 Bipolar Trial; Enveda Receives IND; ICER Obesity ReportPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 16 | 2025Pfizer FY 2026 Investor Call; Kailera Initiates Ph3 Obesity Program; Noom Biomarker Partnership; GLP-1RA Retinopathy LawsuitsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 15 | 2025Lilly Initiates Eloralintide Ph3 Program; CKM Guidelines Published; New CagriSema Ph3 Peds Study; Noom Launches GLP-1RA Longevity ProgramPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Dec 15 | 2025FDA Leadership Pushes for Expedited Orforglipron Review; Novo and Cytokinetics Positive CHMP Opinions; Rezolute Misses Endpoints in Ph3 StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 11 | 2025Zealand 2025 CMD and Partnership for Obesity Drug Discovery; Lilly Shares Topline Retatrutide Results; Corbus Topline CB1 Data; Dexcom Launches G7 15 Day CGM; Prolynx Series A Funding and Names CEOPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, SGLT2i, Topics Dec 10 | 2025Lilly Builds New Site in Alabama; Updated ADA/EASD 2026 Diabetes Guidelines; Novo Registers New Ph1 AssetPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Dec 09 | 2025Pfizer Acquires Oral GLP-1RA; FDA Grants AI Drug Development Tool in MASH; Lilly Discontinues Tempo; Novo Completes Akero Acquisition; Regeneron Registers siRNA Ph2 Study in DKD; December CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Dec 08 | 2025Structure’s Topline Ph2 Aleniglipron Data; Ascletis Reports Topline Data from Ph1 Oral GLP-1RA; BI Advances Triple Agonist for Obesity; Wave Announces Ph1 Data from Muscle-Sparing Asset; Lingo Now Available on Android; Medtronic Shifts Exec to MiniMedPurchase Blast
$599
Posted in: Insulin Delivery, Other, Topics Dec 04 | 2025Insulet O5 Algorithm Updates; BioAge Ph1 NLRP3i DataPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Dec 02 | 2025FDA Accepts AZ’s Baxdrostat NDA and MannKind’s sNDA for FUROSCIX in CHF + CKD; Medtronic Full US Launch for Abbott-Partnered CGM; Plozasiran Breakthrough Therapy Designation; New Fractyl Data; WHO Publishes GLP-1RA GuidelinesPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 02 | 2025Lilly Cuts Zepbound Prices; Cagrisema Ph3 Pediatric Obesity Trial; Ascletis Selects Obesity Candidate; Altimmune Replaces CEO; Olazarsen Breakthrough Therapy Designation; New Ph3 Bofanglutide Study; Ikaria Registers Study for Obesity Asset Monotherapy and Combination with TirzepatidePurchase Blast
$599
Posted in: GLP-1RA, Other, SGLT2i, Topics Nov 26 | 2025Novo Files 7.2mg Wegovy; CMS Cuts Semaglutide Prices; FDA Publishes Marketing Violation LettersPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other, SGLT2i, Topics Nov 25 | 2025Topline Amycretin Ph2 Data in T2DM; Abbott Libre 3/3+ CGM IssuesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
